(Q42322578)

26 October 2017

0 references

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug (English)

1 reference

26 October 2017

1 reference

Michael W Stewart

1

1 reference

PMCID

3432488

26 October 2017

language of work or name

English

0 references

publication date

23 March 2012

1 reference

British Journal of Ophthalmology

26 October 2017

1 reference

26 October 2017

96

1 reference

26 October 2017

9

1 reference

26 October 2017

1157-1158

1 reference

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

Ranibizumab for neovascular age-related macular degeneration

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

VEGF-Trap: a VEGF blocker with potent antitumor effects

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

Predicted biological activity of intravitreal VEGF Trap.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432488

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing

17 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22446028

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22446028

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/BJOPHTHALMOL-2011-300654

1 reference

26 October 2017

1 reference

26 October 2017

1 reference

PMCID

3432488